Tanabe Seiyaku Explores Possible Merger with Mitsubishi Pharma - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Tanabe Seiyaku Explores Possible Merger with Mitsubishi Pharma


ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Tokyo (Jan. 18)Tanabe Seiyaku Co. Ltd. (www.tanabe.co.jp/english) confirmed it has had discussions with Mitsubishi Pharma Corporation (www.m-pharma.co.jp) over a possible merger between the two companies, but that no definite decision has been made for such a deal.

“Tanabe has been discussing with Mitsubishi Pharma on a potential merger between the two companies for the purpose of expansion of business scale and reinforcement of management infrastructure to respond to the competitive environment surrounding the pharmaceutical market and survive intensifying global competition,” said Tanabe Seiyaku in a prepared statement. “However, no concrete decision has been made in this regard.”

A potential merger between Tanabe Seiyaku and Mitsubishi Pharma follows recent consolidation in the Japanese pharmaceutical industry. In 2005, Sanyko and Daiichi Pharmaceuticals merged to form Daiichi Sanyko Co. Ltd. (Tokyo, www.daiichipharm.co.jp/english), and Fujisawa Pharmaceutical Co., Ltd. and Yamanouchi Pharmaceutical Co., Ltd. merged to form Astellas Pharma Inc. (Tokyo, www.astellas.com).

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here